Skip to main content

Table 2 Synovial and skin immunohistological expression of CD3, CD4, CD8, FOXP3 and CD31 prior to and following abatacept treatment

From: Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis

 

Baseline

2 Months

6 Months

P value

0 vs 2 months

0 vs 6 months

ABA

PBO

ABA

PBO

ABA

ABA

PBO

ABA

Synovium

 CD3

2.66 (±1.2)

1.8 (±0.8)

2.3 (±1)

2.25 (±1.5)

2.22 (±1.3)

0.679

0.824

0.739

 CD4

2.83 (±1.2)

2.4 (±1.5)

2.3 (±0.8)

2.75 (±1.3)

1.78 (±1.1)

0.296

1

0.073

 CD8

1.66 (±0.8)

2 (±1)

1.3 (±1)

1.75 (±1)

1.33 (±0.7)

0.576

0.604

0.129

 FOXP3

5 (±6)

4.4 (±4.4)

2.8 (±2.2)

4.6 (±4)

1.13 (±2.4)

0.407

0.807

0.027*

 CD31

78.3 (±53.9)

85.6 (±50.2)

67.6 (±75.9)

155.5 (±136)

73.22 (±69.9)

0.621

0.482

0.813

Skin

 CD3

2.6 (±0.8)

2.4 (±0.9)

2.25 (±1.5)

2.5 (±2.1)

2.43 (±1.1)

0.718

0.717

0.891

 CD4

3.5 (±0.5)

2.8 (±1.1)

2.75 (±0.9)

4 (±0)

3.14 (±0.9)

0.182

1

0.891

 CD8

2 (±0.6)

1.75 (±1)

1.5 (±0.6)

2 (±1.4)

1.71 (±0.8)

0.718

0.423

0.577

 FOXP3

16 (±9.5)

9.2 (±10.7)

9.5 ±4.5

17.5 ±2.1

13.14 ±8.3

0.743

0.709

0.497

 CD31

61.2 (±38)

65.4 (±20.5)

75.5 ±17.1

64.5 ±10.6

54.71 ±17.2

0.788

0.749

0.612

  1. The Wilcoxon test and the paired sample t test were used for analysis. Results are presented as mean ± SD
  2. Number of ABA samples at 0, 2 and 6 months: synovial n = 7, n = 6, n = 9; skin n = 6, n = 5, n = 7, respectively. Number of PBO samples at 0 and 2 months: synovial n = 7, n = 5; skin n = 5, n = 4, respectively. Expression of CD3, CD4 and CD8 was scored on a 5-point scale (0–4). CD31 expression was scored by the number of positive vessels/10 high power fields. Forkhead box protein transcription factor 3 (FOXP3) expression was scored as %/300 cells. ABA abatacept group, PBO placebo group. *Statistically significant